The Current Ratio as of September 2024 (TTM) for ImmunoGen, Inc. (IMGN) is 5.47

According to ImmunoGen, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.47. This represents a change of 38.33% compared to the average of 3.95 of the last 4 quarters.

ImmunoGen, Inc. (IMGN) Historical Current Ratio (quarterly & annually)

How has IMGN Current Ratio performed in the past?

The mean historical Current Ratio of ImmunoGen, Inc. over the last ten years is 3.94. The current 5.47 Current Ratio has changed 13.77% with respect to the historical average. Over the past ten years (40 quarters), IMGN's Current Ratio was at its highest in in the December 2013 quarter at 10.10. The Current Ratio was at its lowest in in the March 2023 quarter at 1.98.

ImmunoGen, Inc. (IMGN) Current Ratio by Quarter and Year

Discovering the peaks and valleys of ImmunoGen, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

ImmunoGen, Inc. (IMGN) Average Current Ratio

How has IMGN Current Ratio performed in the past?

The current Current Ratio of ImmunoGen, Inc. (IMGN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

ImmunoGen, Inc. (IMGN) Current Ratio vs. Peers

How is IMGN’s Current Ratio compared to its peers?

ImmunoGen, Inc.’s Current Ratio is less than Madrigal Pharmaceuticals, Inc. (8.72), greater than Intercept Pharmaceuticals, Inc. (4.22), greater than TG Therapeutics, Inc. (3.58), less than Terns Pharmaceuticals, Inc. (21.02), less than Hepion Pharmaceuticals, Inc. (5.62), less than Viking Therapeutics, Inc. (37.69), greater than Axsome Therapeutics, Inc. (2.48), greater than Seres Therapeutics, Inc. (1.38), less than Mereo BioPharma Group plc (6.07), greater than PDS Biotechnology Corporation (3.84), less than Inozyme Pharma, Inc. (9.84), greater than HOOKIPA Pharma Inc. (3.86), greater than eFFECTOR Therapeutics, Inc. (1.03), less than X4 Pharmaceuticals, Inc. (6.07), less than Elevation Oncology, Inc. (41.10), less than Akero Therapeutics, Inc. (24.89), greater than Reata Pharmaceuticals, Inc. (3.21),

Build a custom stock screener for ImmunoGen, Inc. (IMGN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunoGen, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ImmunoGen, Inc. (IMGN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ImmunoGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.